Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Hunter Syndrome Treatment Market Growth & Trends

The global hunter syndrome treatment market size is expected to reach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.

Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births.

Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc’s Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea.

Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA’s Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.

Hunter Syndrome Treatment Market Report Highlights

• The intravenous segment led the market and accounted for the largest revenue share of 72.3% in 2024 attributed to its established effectiveness in delivering enzyme replacement therapies (ERT).
• Enzyme replacement therapy (ERT) led the market and accounted for the largest revenue share of 57.3% in 2024 driven by its ability to address the deficiency of the enzyme iduronate-2-sulfatase.
• Hospitals held the dominant position in the market, accounting for the largest revenue share of 63.1% in 2024 attributed to their capacity to provide comprehensive care and advanced medical resources.
• North America hunter syndrome treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to a combination of advanced healthcare infrastructure and increasing awareness of rare diseases.

Please note The report will be delivered in 2-3 business days upon order notification.